Stay informed, stay ahead.
British pharmaceutical giant GSK has lifted its full-year 2025 guidance after a strong third quarter. Sales jumped thanks to double-digit growth in its HIV and cancer drug portfolios. The company reported Q3 revenue of about £8.55 billion, beating market expectations. Core earnings per share reached 55 pence, up significantly from the same quarter last year. …
GSK, the major global pharmaceutical company, is on the brink of a significant victory. The company is expected to receive US Food and Drug Administration (FDA) approval for its new blood cancer treatment. A Boost for Patients This FDA approval marks a major win for patients battling blood cancer. The new treatment is likely targeted…
The UK’s health watchdog, NICE, has approved ViiV Healthcare’s HIV prevention injection, Apretude, paving the way for its rollout on the National Health Service (NHS) in England and Wales. Apretude, developed by GSK’s ViiV Healthcare unit, is designed for pre-exposure prophylaxis (PrEP) — a treatment that prevents HIV infection in people at high risk. Unlike…
